Biomarin Pharmaceutical
BMRN
55.20
-1.02
-1.81%
Biomarin Pharmaceutical
US · BMRN
#1379 by market cap
Listed 1970
55.20
-1.02
-1.81%
Live - 5344 symbols - heartbeat 439s ago
· 2026-10-08 07:00
Pre-market
55.05
-0.27%
After-hours
55.55
+0.63%
- Market cap
- 10.69B
- P/E (TTM)i
- 145.26
- P/Bi
- 1.69
- EPSi
- 1.80
- Div yieldi
- 0.00%
- 52W posi
- 27%
Reader sentiment
Are you bullish or bearish on BMRN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.39, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +12.87% YoY
Margins
- Gross margin
- 77.73%
- Operating margin
- 12.71%
- Net margin
- 10.83%
Key ratios & quality
- Enterprise valuei
- 9.73B
- PEG ratioi
- 4.14
- Altman Z-Scorei
- 5.39
PEG uses trailing P/E against the 3-year net income growth rate (35.08%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.49B | 1.70B | 1.86B | 1.85B | 2.10B | 2.42B | 2.85B | 3.22B |
| Gross profit | 1.18B | 1.34B | 1.34B | 1.38B | 1.59B | 1.89B | 2.27B | 2.50B |
| Selling & admin expenses | 604.40M | 680.90M | 737.70M | 759.40M | 823.20M | 892.40M | 1.01B | 1.15B |
| Research & development | 696.33M | 715.01M | 628.12M | 628.79M | 649.61M | 746.77M | 747.18M | 921.93M |
| Operating profit | -155.04M | -104.83M | -91.83M | -74.33M | 57.41M | 185.78M | 474.24M | 409.50M |
| Pretax profit | -142.71M | -94.81M | -49.00M | -75.35M | 149.58M | 188.56M | 541.76M | 482.48M |
| Tax | -65.49M | -70.96M | -903.03M | -11.27M | 8.02M | 20.92M | 114.90M | 133.58M |
| Net profit | -77.21M | -23.85M | 854.03M | -64.08M | 141.56M | 167.65M | 426.86M | 348.90M |
| Basic EPS | 0 | 0 | 5 | 0 | 1 | 1 | 2 | 2 |
| Diluted EPS | -0.44 | -0.13 | 4.50 | -0.35 | 0.75 | 0.87 | 2.21 | 1.80 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 745.15M | 825.41M | 776.13M | 874.57M | 766.21M | 989.71M |
| Gross profit | 593.59M | 675.32M | 636.05M | 598.86M | 571.21M | 786.91M |
| Selling & admin expenses | 206.10M | 232.30M | 268.40M | 446.20M | 258.30M | 395.50M |
| Research & development | 158.73M | 161.31M | 409.48M | 192.41M | 178.80M | 206.95M |
| Operating profit | 223.91M | 276.87M | -46.68M | -44.60M | 129.63M | 110.97M |
| Pretax profit | 238.09M | 297.87M | -26.32M | -27.15M | 141.20M | 61.38M |
| Tax | 52.40M | 57.34M | 4.42M | 19.42M | 35.68M | 16.62M |
| Net profit | 185.69M | 240.53M | -30.74M | -46.57M | 105.53M | 44.76M |
| Basic EPS | 1 | 1 | 0 | 0 | 1 | 0 |
| Diluted EPS | 0.95 | 1.23 | -0.16 | -0.24 | 0.54 | 0.23 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.06B | 1.94B | 2.34B | 2.27B | 2.75B | 2.96B | 3.23B | 3.95B |
| Cash & ST investments | 1.08B | 753.81M | 1.07B | 1.01B | 1.29B | 1.07B | 1.14B | 1.56B |
| Inventory | 530.87M | 680.28M | 698.55M | 776.67M | 894.08M | 1.11B | 1.23B | 1.30B |
| Total assets | 4.43B | 4.69B | 5.85B | 6.00B | 6.38B | 6.84B | 6.99B | 7.59B |
| Total current liabilities | 523.24M | 932.50M | 492.55M | 546.50M | 588.88M | 1.18B | 606.99M | 759.03M |
| Short-term debt | -- | 372.58M | 11.75M | 10.46M | 10.38M | 502.66M | 7.57M | 8.69M |
| Long-term debt | 830.42M | 486.24M | 1.08B | 1.08B | 1.08B | 593.10M | 595.14M | 597.18M |
| Total liabilities | 1,459,188,000.00 | 1,567,658,000.00 | 1,742,018,000.00 | 1,739,103,000.00 | 1,771,918,000.00 | 1,890,054,000.00 | 1,330,950,000.00 | 1,507,023,000.00 |
| Total equity | 2.97B | 3.12B | 4.11B | 4.27B | 4.60B | 4.95B | 5.66B | 6.09B |
| Retained earnings | -1.69B | -1.72B | -861.61M | -930.76M | -789.20M | -621.55M | -194.70M | 154.21M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.47B | 3.81B | 3.85B | 3.95B | 4.61B | 3.97B |
| Cash & ST investments | 1.27B | 1.43B | 1.48B | 1.56B | 2.22B | 874.01M |
| Inventory | 1.27B | 1.34B | 1.38B | 1.30B | 1.27B | 1.78B |
| Total assets | 7.15B | 7.46B | 7.61B | 7.59B | 8.59B | 11.72B |
| Total current liabilities | 628.21M | 684.25M | 798.44M | 759.03M | 793.15M | 1.66B |
| Short-term debt | 6.31M | 7.70M | 7.58M | 8.69M | 9.32M | 674.26M |
| Long-term debt | 595.65M | 596.16M | 596.66M | 597.18M | 1.43B | 3.53B |
| Total liabilities | 1,353,548,000.00 | 1,429,228,000.00 | 1,558,157,000.00 | 1,507,023,000.00 | 2,378,909,000.00 | 5,401,750,000.00 |
| Total equity | 5.79B | 6.03B | 6.06B | 6.09B | 6.21B | 6.32B |
| Retained earnings | -9.01M | 231.52M | 200.78M | 154.21M | 259.73M | 304.50M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 20.21M | 48.26M | 85.37M | 304.54M | 175.90M | 159.26M | 572.84M | 827.99M |
| Depreciation & amortization | 95.67M | 105.30M | 105.17M | 108.04M | 101.97M | 104.39M | 96.43M | 79.56M |
| Free cash flow | -124.41M | -115.14M | -52.15M | 185.31M | 44.36M | 51.65M | 475.42M | 717.02M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -50.00M | -- | -- | -- | -- | -- |
| Ending cash balance | 493.98M | 437.45M | 649.16M | 587.28M | 724.53M | 755.13M | 942.84M | 1.31B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 174.39M | 185.27M | 368.69M | 99.64M | 220.65M | 168.11M |
| Depreciation & amortization | 22.07M | 18.56M | 18.49M | 20.44M | 16.41M | 97.64M |
| Free cash flow | 157.63M | 167.90M | 334.94M | 56.55M | 199.73M | 133.86M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 1.05B | 1.21B | 1.25B | 1.31B | 3.07B | 874.01M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -2.67 | -0.78 | 23.77 | -1.53 | 3.19 | 3.51 | 8.05 | 5.94 |
| ROA %i | -1.70 | -0.52 | 16.30 | -1.08 | 2.29 | 2.54 | 6.17 | 4.79 |
| ROIC %i | -1.74 | -0.61 | 18.93 | -1.15 | 2.52 | 2.23 | 6.14 | 4.67 |
| 5-year avg ROE %i | -9.87 | -8.16 | -1.68 | 2.89 | 4.37 | 5.60 | 7.37 | 3.83 |
| EBIT margin %i | -6.88 | -4.31 | -0.70 | -3.28 | 7.87 | 8.49 | 19.42 | 15.32 |
| FCF / sales %i | -- | -- | -- | 10.04 | 2.12 | 2.13 | 16.66 | 22.26 |
| Current ratioi | 3.93 | 2.08 | 4.76 | 4.16 | 4.67 | 2.51 | 5.33 | 5.21 |
| Quick ratioi | 2.73 | 1.21 | 3.07 | 2.54 | 2.98 | 1.45 | 2.96 | 3.25 |
| Debt / assetsi | 18.76 | 18.31 | 18.59 | 18.14 | 17.15 | 16.02 | 8.62 | 7.98 |
| LT debt / equityi | 27.98 | 15.57 | 26.18 | 25.30 | 23.53 | 11.98 | 10.52 | 9.81 |
| Interest coveragei | -2.56 | -3.42 | -0.44 | -4.11 | 10.73 | 12.26 | 44.91 | 45.27 |
| Revenue CAGR (3Y) %i | 18.78 | 15.12 | 12.30 | 7.38 | 7.15 | 9.15 | 15.62 | 15.40 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -41.88 | -- | 35.08 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | 36.90 | 152.84 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 9.64 | 11.62 | 9.07 | 5.94 | 4.48 | 1.18 |
| ROA %i | 7.47 | 9.05 | 7.20 | 4.79 | 3.42 | 0.76 |
| ROIC %i | 7.56 | 9.34 | 7.45 | 4.67 | 3.28 | 0.95 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 23.25 | 27.77 | 22.29 | 15.32 | 12.60 | 6.83 |
| FCF / sales %i | 21.02 | 22.56 | 26.69 | 22.26 | 23.41 | 21.28 |
| Current ratioi | 5.52 | 5.56 | 4.83 | 5.21 | 5.81 | 2.39 |
| Quick ratioi | 3.20 | 3.34 | 2.84 | 3.25 | 3.94 | 1.16 |
| Debt / assetsi | 8.42 | 8.10 | 7.94 | 7.98 | 16.76 | 35.84 |
| LT debt / equityi | 10.28 | 9.89 | 9.85 | 9.81 | 23.02 | 55.81 |
| Interest coveragei | 58.86 | 79.07 | 66.50 | 45.27 | 17.77 | 2.78 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Voxzogo is the largest reported line at 25.52% of revenue, across 10 reported segments.
- No single line clears half of revenue; Vimizim is next at 19.64%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Voxzogo25.52%
Vimizim19.64%
Naglazyme13.67%
Palynziq13.66%
GALAFOLD10.68%
Brineura5.19%
ALDURAZYME4.40%
POMBILITI + OPFOLDA3.06%
Kuvan2.47%
Other1.72%
Quote time 2026-10-08 07:00:00 · For reference only, not investment advice and not tailored to your situation.